Crescent Biopharma reported Q3 2026 financial results and provided clinical updates on its lead programs, including the completion of dose escalation for CR-001 in the Phase 1/2 ASCEND trial. The company expects initial monotherapy data for CR-001 in Q1 2027 and highlighted that over 2,000 patients are expected to be dosed across its portfolio by mid-2027.
Counterparty
Kelun-Biotech
“This has been a defining year for Crescent. We advanced three programs into the clinic and established a leading position in developing next generation IO and ADC combinations which we believe have the potential to redefine cancer care. Together with our partner Kelun-Biotech, we have achieved a remarkable nine IND clearances, and anticipate that more than 2,000 patients will be dosed across our portfolio by mid-2027.”
Joshua Brumm, chief executive officer of Crescent
“The team’s strong execution has positioned us for several meaningful clinical data readouts in 2027, beginning in the first quarter with monotherapy results from our global ASCEND trial of CR-001, including first-line NSCLC patients, followed by initial standard of care chemotherapy combination data from multiple tumor types.”
Crescent Biopharma, Inc. is a clinical-stage biotechnology company focused on developing its lead program, CR-001, and other product candidates. The company has a limited operating history, has never generated revenue from product sales, and anticipates continued losses for the foreseeable future as it advances its clinical trials.
Crescent Biopharma provided a comprehensive clinical pipeline update, including the commencement of chemotherapy combination cohorts in its Phase 1/2 ASCEND trial for CR-001. The company also announced the initiation of combination studies with Kelun-Biotech and set expectations for initial monotherapy data readouts in Q1 2027.
Crescent Biopharma CMO Ellie Eunkyung Im Sells $11.2K of Stock
Ellie Eunkyung Im, CMO, sold 623 shares of Crescent Biopharma, Inc. at $17.90 a share, worth $11.2K in total on Sep 16, 2026. Shares held after the trade: 21,446 (-2.8%).
Crescent Biopharma President and COO Jonathan McNeill Sells $77.2K of Stock
Jonathan McNeill, President and COO, sold 4,570 shares of Crescent Biopharma, Inc. at $16.71 to $17.90 a share (average $16.90) in 2 transactions, worth $77.2K in total between Sep 16, 2026 and Sep 18, 2026. Shares held after the trade: 134,588 (-2.8%).
Crescent Biopharma CFO Richard William Scalzo Sells $10.2K of Stock
Richard William Scalzo, CFO, sold 568 shares of Crescent Biopharma, Inc. at $17.90 a share, worth $10.2K in total on Sep 16, 2026. Shares held after the trade: 19,730 (-2.8%).
Crescent Biopharma CEO Joshua T. Brumm Sells $160K of Stock
Joshua T. Brumm, CEO, sold 9,447 shares of Crescent Biopharma, Inc. at $16.71 to $17.90 a share (average $16.91) in 2 transactions, worth $160K in total between Sep 16, 2026 and Sep 18, 2026. Shares held after the trade: 271,765 (-2.8%).
Crescent Biopharma Insider Barbara Harlin Bispham Sells $11.1K of Stock
Barbara Harlin Bispham sold 620 shares of Crescent Biopharma, Inc. at $17.90 a share, worth $11.1K in total on Sep 16, 2026. Shares held after the trade: 18,710 (-3.2%).